{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:06:44Z","timestamp":1792786004689,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute on Drug Abuse of the National Institutes of Health","award":["K24DA057874"],"award-info":[{"award-number":["K24DA057874"]}]},{"name":"National Institutes of Allergy and Infectious Diseases","award":["K01AI182507"],"award-info":[{"award-number":["K01AI182507"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Testosterone gender-affirming hormone therapy frequently results in genital atrophy among transmasculine individuals. Low-dose topical genital estrogen is currently recommended for transmasculine individuals experiencing dyspareunia and vaginitis, but its effectiveness has not been assessed among those using testosterone. The objective of this study was to describe the lived experience of genital atrophy and the acceptability of available treatments in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted in-depth one-on-one interviews with 28 transmasculine adults using testosterone, recruited through PRIDEnet, an established national LGBTQIA+ community-engagement network. Participants were asked questions related to their lived experiences of genital atrophy, including symptom recognition, experiences seeking care, and treatment preferences using a structured interview guide. Transcribed interviews were analyzed using qualitative thematic analysis and content analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nearly all participants (93%) had heard of genital atrophy and 64% had ever experienced it in their lifetimes (46% in the past year). Symptoms ranged from transient dryness and discomfort during penetrative sex to chronic pain affecting walking, sitting, urination, and daily functioning. Most participants (79%) had heard of topical genital estrogen; 43% had ever used it, and most reported symptomatic relief. Cream was the most commonly prescribed but least preferred formulation due to messiness, dysphoria associated with genital contact, and interference with sexual activity; suppository tablets and the genital ring were most preferred. Concerns about systemic estrogen absorption and interference with testosterone were pervasive. Participants encountered significant treatment barriers including providers who lacked knowledge of genital atrophy in transmasculine patients, minimized or dismissed symptoms, or refused to prescribe topical genital estrogen. Insurance denials, formulation restrictions, and negative pharmacy interactions represented additional barriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The provider knowledge gaps and systemic barriers documented in this study underscore that improving genitourinary health outcomes for transmasculine individuals will require concurrent advances in medical education, insurance policy, and clinical evidence. Clinicians should proactively counsel transmasculine patients about genital atrophy at testosterone initiation and discuss all available treatment formulations with explicit attention to gender dysphoria, systemic absorption concerns, and insurance constraints. Provider education on the genitourinary effects of testosterone and the diagnosis and treatment of genital atrophy must improve across clinical training programs. Clinical trials evaluating the efficacy, systemic absorption, and acceptability of all available treatment options \u2014 including topical estrogen formulations, dehydroepiandrosterone, and ospemifene \u2014 among transmasculine individuals using testosterone are urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdag308","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:23:20Z","timestamp":1789673000000},"source":"Crossref","is-referenced-by-count":0,"title":["Genital atrophy in transmasculine individuals using testosterone: symptom experiences, treatment preferences, and barriers to care"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9238-9927","authenticated-orcid":false,"given":"Diana M","family":"Tordoff","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]},{"name":"The PRIDE Study\/PRIDEnet, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7042-2319","authenticated-orcid":false,"given":"Meg","family":"Quint","sequence":"additional","affiliation":[{"name":"The PRIDE Study\/PRIDEnet, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]},{"name":"Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Oscar","family":"Anderson","sequence":"additional","affiliation":[{"name":"The PRIDE Study\/PRIDEnet, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]},{"name":"Community Healthcare Network , New York, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alic","family":"Shook","sequence":"additional","affiliation":[{"name":"College of Nursing & Health Sciences, Seattle University , Seattle, WA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1964-4151","authenticated-orcid":false,"given":"Annesa","family":"Flentje","sequence":"additional","affiliation":[{"name":"The PRIDE Study\/PRIDEnet, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]},{"name":"Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0068-0814","authenticated-orcid":false,"given":"Mitchell R","family":"Lunn","sequence":"additional","affiliation":[{"name":"The PRIDE Study\/PRIDEnet, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]},{"name":"Division of Nephrology, Department of Medicine, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]},{"name":"Department of Epidemiology and Population Health, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0945-2842","authenticated-orcid":false,"given":"Juno","family":"Obedin-Maliver","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]},{"name":"The PRIDE Study\/PRIDEnet, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]},{"name":"Department of Epidemiology and Population Health, Stanford University School of Medicine , Palo Alto, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"2","key":"2026093010031633000_ref1","doi-asserted-by":"publisher","first-page":"229.e1","DOI":"10.1016\/j.ajog.2020.01.059","article-title":"The effect of testosterone on ovulatory function in transmasculine individuals","volume":"223","author":"Taub","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2026093010031633000_ref2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/AOG.0000000000000692","article-title":"Effects of cross-sex hormone treatment on transgender women and men","volume":"125","author":"Deutsch","year":"2015","journal-title":"Obstet Gynecol"},{"key":"2026093010031633000_ref3","doi-asserted-by":"publisher","DOI":"10.3389\/FCIMB.2021.769950","article-title":"The effect of gender-affirming medical care on the vaginal and neovaginal microbiomes of transgender and gender-diverse people","volume":"11","author":"Krakowsky","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"2026093010031633000_ref4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.5858\/arpa.2021-0199-OA","article-title":"Histologic findings in gynecologic tissue from transmasculine individuals undergoing gender-affirming surgery","volume":"146","author":"Lin","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"2026093010031633000_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqac107","article-title":"Microscopic features of vaginectomy specimens from transgender patients","volume":"158","author":"Dasaraju","year":"2022","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"2026093010031633000_ref6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/dc.25030","article-title":"Cervicovaginal cytology, HPV testing and vaginal flora in transmasculine persons receiving testosterone","volume":"50","author":"Lin","year":"2022","journal-title":"Diagn Cytopathol"},{"issue":"11","key":"2026093010031633000_ref7","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/ gender-incongruent persons: an endocrine society*clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026093010031633000_ref8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf114","article-title":"The impact of testosterone therapy on the vaginal microbiota of transgender men and nonbinary people: a prospective study","volume":"232","author":"Van Gerwen","year":"2025","journal-title":"J Infect Dis"},{"issue":"12","key":"2026093010031633000_ref9","doi-asserted-by":"publisher","first-page":"116632","DOI":"10.1016\/j.celrep.2025.116632","article-title":"The vaginal microbiota, symptoms, and local immune correlates in transmasculine individuals using sustained testosterone therapy","volume":"44","author":"Monari","year":"2025","journal-title":"Cell Rep"},{"issue":"6","key":"2026093010031633000_ref10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ajog.2023.08.035","article-title":"Testosterone use and sexual function among transgender men and gender diverse people assigned female at birth","volume":"229","author":"Tordoff","year":"2023","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"2026093010031633000_ref11","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.7759\/cureus.7586","article-title":"The genitourinary syndrome of menopause: an overview of the recent data","volume":"12","author":"Angelou","year":"2020","journal-title":"Cureus."},{"key":"2026093010031633000_ref12","article-title":"Pelvic pain and persistent menses in transgender men","author":"Obedin-Maliver","year":"2016","journal-title":"UCSF Transgender Care & Treatment Guidelines"},{"issue":"3","key":"2026093010031633000_ref13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/SPV.0B013E3181AB4804","article-title":"Local effects of vaginally administered estrogen therapy: a review","volume":"15","author":"Krause","year":"2009","journal-title":"J Pelvic Med Surg"},{"issue":"3","key":"2026093010031633000_ref14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/SPV.0B013E3181D7E86E","article-title":"Systemic effects of vaginally administered estrogen therapy: a review","volume":"16","author":"Krause","year":"2010","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"9","key":"2026093010031633000_ref15","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0136265","article-title":"Local oestrogen for pelvic floor disorders: a systematic review","volume":"10","author":"Weber","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"2026093010031633000_ref16","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.7326\/ANNALS-24-00610","article-title":"Hormonal treatments and vaginal moisturizers for genitourinary syndrome of menopause\u00a0: a systematic review","volume":"177","author":"Danan","year":"2024","journal-title":"Ann Intern Med"},{"issue":"5","key":"2026093010031633000_ref17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/ijir.2013.9","article-title":"Effects of long-term high dose testosterone administration on vaginal epithelium structure and estrogen receptor-\u03b1 and -\u03b2 expression of young women","volume":"25","author":"Baldassarre","year":"2013","journal-title":"Int J Impot Res"},{"issue":"1","key":"2026093010031633000_ref18","doi-asserted-by":"publisher","first-page":"21526","DOI":"10.1038\/s41598-024-72365-4","article-title":"The vaginal microbiome of transgender men receiving gender-affirming hormonal therapy in comparison to that of cisgender women","volume":"14","author":"Feil","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"2026093010031633000_ref19","doi-asserted-by":"publisher","first-page":"qdag047","DOI":"10.1093\/jsxmed\/qdag047","article-title":"Vaginal estrogen therapy among transgender and nonbinary assigned female at birth individuals: use, effectiveness, and hesitations","volume":"23","author":"Abern","year":"2026","journal-title":"J Sex Med"},{"key":"2026093010031633000_ref20","doi-asserted-by":"publisher","first-page":"106071","DOI":"10.1016\/j.ypmed.2020.106071","article-title":"Barriers and facilitators to cervical cancer screening among transgender men and non-binary people with a cervix: a systematic narrative review","volume":"135","author":"Connolly","year":"2020","journal-title":"Prev Med"},{"key":"2026093010031633000_ref21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1089\/lgbt.2016.0143","volume-title":"LGBT Health","author":"Seay","year":"2017"},{"issue":"2","key":"2026093010031633000_ref22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/JAMIA\/OCAB150","article-title":"Online health information seeking, health literacy, and human papillomavirus vaccination among transgender and gender-diverse people","volume":"29","author":"Pho","year":"2022","journal-title":"J Am Med Inform Assoc"},{"key":"2026093010031633000_ref23","doi-asserted-by":"publisher","first-page":"119672","DOI":"10.1016\/j.socscimed.2026.119672","article-title":"\u201cI don\u2019t know how to treat you\u201d: testosterone and gynecological care for transmasculine and gender diverse adults","volume":"406","author":"Tordoff","year":"2026","journal-title":"Soc Sci Med"},{"issue":"2","key":"2026093010031633000_ref24","doi-asserted-by":"publisher","DOI":"10.54656\/jces.v16i2.484","article-title":"Engaging sexual and gender minority (SGM) communities for Health Research","volume":"16","author":"Obedin-Maliver","year":"2024","journal-title":"Building and Sustaining PRIDEnet"},{"issue":"3","key":"2026093010031633000_ref25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jsxm.2017.01.011","article-title":"The Women\u2019s EMPOWER survey: Women\u2019s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate","volume":"14","author":"Krychman","year":"2017","journal-title":"J Sex Med"},{"key":"2026093010031633000_ref26","doi-asserted-by":"publisher","first-page":"100525","DOI":"10.1016\/j.ssmph.2019.100525","article-title":"Correlations between healthcare provider interactions and mental health among transgender and nonbinary adults","volume":"10","author":"Kattari","year":"2020","journal-title":"SSM - Popul Health"},{"issue":"1","key":"2026093010031633000_ref27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1089\/trgh.2020.0018","article-title":"Transgender education experiences among obstetrics and gynecology residents: a National Survey","volume":"7","author":"Burgart","year":"2022","journal-title":"Transgend Health"},{"issue":"4","key":"2026093010031633000_ref28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1089\/trgh.2020.0063","article-title":"Are obstetrics and gynecology residents equipped to care for transgender and gender nonconforming patients? A National Survey Study","volume":"6","author":"Qin","year":"2021","journal-title":"Transgend Health"},{"key":"2026093010031633000_ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-025-00800-3","article-title":"Patient preferences regarding menopausal symptoms and treatments: a systematic review of quantitative stated-preference studies","volume":"19","author":"Raskin","year":"2026","journal-title":"The Patient"},{"issue":"11","key":"2026093010031633000_ref30","doi-asserted-by":"publisher","first-page":"e2241743","DOI":"10.1001\/jamanetworkopen.2022.41743","article-title":"Association of vaginal estradiol tablet with serum estrogen levels in women who are postmenopausal: secondary analysis of a randomized clinical trial","volume":"5","author":"Mitchell","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2026093010031633000_ref31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/GME.0000000000001463","article-title":"Systemic estradiol levels with low-dose vaginal estrogens","volume":"27","author":"Santen","year":"2020","journal-title":"Menopause."},{"key":"2026093010031633000_ref32","doi-asserted-by":"publisher","first-page":"116261","DOI":"10.1016\/j.ejca.2026.116261","article-title":"Vaginal tamoxifen - a potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen","volume":"236","author":"Nyback","year":"2026","journal-title":"Eur J Cancer"},{"issue":"7","key":"2026093010031633000_ref33","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/GME.0000000000000613","article-title":"Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial","volume":"23","author":"Fernandes","year":"2016","journal-title":"Menopause N Y N"},{"issue":"3","key":"2026093010031633000_ref34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"2026093010031633000_ref35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/AOG.0000000000005940","article-title":"Postpartum and lactation-related genitourinary symptoms: a systematic review","volume":"146","author":"Perelmuter","year":"2025","journal-title":"Obstet Gynecol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/10\/qdag308\/71523215\/qdag308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/10\/qdag308\/71523215\/qdag308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:03:27Z","timestamp":1790777007000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/doi\/10.1093\/jsxmed\/qdag308\/8853850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,14]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdag308","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,14]]},"article-number":"qdag308"}}